Search results
Results from the WOW.Com Content Network
With several key data updates expected in 2025, the stock appears well-positioned for long-term growth, the analyst adds. ... and a price target of $172. BioNTech’s oncology pipeline was ...
Price Action: BNTX stock is up 5.87% at $112.57 at the last check on Wednesday. Read Next: Regeneron/Sanofi’s Dupixent Approval Signals Major Treatment Breakthrough For Smokers’ Lung Disease
Monday, BioNTech SE (NASDAQ:BNTX) reported a first-quarter EPS loss of 1.31 euros ($1.41 loss), a shift from an income of 2.05 euros, missing the consensus loss of 97 cents. The COVID-19 vaccine ...
For premium support please call: 800-290-4726 more ways to reach us
BioNTech is scheduled to provide detailed full-year 2024 guidance alongside its 2023 financial results on March 20. ($1 = 0.9141 euros) (Editing by Rachel More and Matthias Williams)
Price Action: BNTX shares are trading 9.5% higher at $201.1 in the premarket session on the last check Monday See more from BenzingaClick here for options trades from BenzingaEMA Safety Committee ...
Coronavirus is a global pandemic. With nearly 220,000 patients infected with COVID-19 at last report (according to Johns Hopkins University data), the populations of 158 countries affected, and ...
Following is a list of company earnings scheduled for release August 9-13, along with earnings previews for select companies. Next week’s earnings are of much significance for major market ...